Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

daratumumab 3Dexamethasone 3Bortezomib 2sodium thiosulfate 1pomalidomide 1pembrolizumab 1etoposide phosphate 1darlin protein, Dictyostelium 1bosutinib 1Thalidomide 1Restraint, Physical 1Pemetrexed 1Mitoxantrone 1Lenalidomide 1Gemtuzumab 1Etoposide 1Daunorubicin 1Cytarabine 1Crizotinib 1Cisplatin 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has announcements × etoposide phosphate × Clear all
NCT00372593 2021-03-24

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Children's Oncology Group

Phase 3 Completed
1,070 enrolled 18 charts 1 FDA
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡